Pharming Group Q3 total revenues up at $117.6 mln
PHAR•Pharming Group reported Q3 2026 revenue of $117.6 million, up 21% and above market expectations. It tightened 2026 revenue guidance to $380 million-$390 million and lowered operating expense guidance to $310 million-$315 million.
1. Quarterly results and outlook
Pharming Group reported Q3 2026 total revenues of $117.6 million, up 21%, and total operating expenses of about $74.6 million. The company tightened its 2026 total revenue guidance to $380 million-$390 million and lowered its total operating expense guidance to $310 million-$315 million.
